10X Genomics Inc expected to post a loss of 46 cents a share - Earnings Preview

10x Genomics

01/11/2023 02:43

* 10X Genomics Inc  TXG.OQ   TXG.O  is expected to show a
rise in
quarterly revenue when it reports  results 
    * The Pleasanton California-based  company is expected to
report 
a 15.4% increase in revenue to $151.264 million from $131.07
million a year ago, according to the mean estimate from 10
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for 10X Genomics Inc is
for a
loss of 46 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for 10X
Genomics Inc
is $65​, above​ its last closing price of $35.28. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.41       -0.40      -0.53     Missed  -31.3
 Mar. 31 2023  -0.35       -0.37      -0.44     Missed  -17.7
 Dec. 31 2022  -0.30       -0.31      -0.15     Beat    51.9​
 Sep. 30 2022  -0.47       -0.46      -0.37     Beat    20.3
 ​​Jun.        -0.40       -0.39      -0.57     Missed  -46.9
 30 2022                                                
 Mar. 31 2022  -0.33       -0.31      -0.38     Missed  -21.5​
 Dec. 31 2021  -0.11       -0.09      -0.16     Missed  -85.2
 Sep. 30 2021  -0.19       -0.20      -0.15     Beat    25.9
 This summary was machine generated November 1 at 02:42 GMT.  All
figures in US dollars  unless otherwise stated